Imexon - AmpliMed

Drug Profile

Imexon - AmpliMed

Alternative Names: Amplimexon; BM 06002

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AmpliMed
  • Class Antineoplastics; Antivirals; Hexanones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Reactive oxygen species stimulants; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Multiple myeloma; Ovarian cancer; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Lung cancer; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer
  • Discontinued Pancreatic cancer

Most Recent Events

  • 04 Aug 2015 No recent reports on development identified - Phase-I for Breast cancer, Lung cancer and Prostate cancer in USA (IV)
  • 04 Aug 2015 No recent reports on development identified - Phase-I/II for Malignant melanoma, Multiple myeloma, and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top